Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-06-2017 | Review Article

Platelet Derived Biomaterials for Therapeutic Use: Review of Technical Aspects

Authors: Satyam Arora, Naveen Agnihotri

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2017

Abstract

Whole blood is composed of both cellular and plasma components, providing a rich source of therapeutic products. Of late, platelet derived biomaterial (platelet rich plasma) consisting of plasma proteins and platelets are increasingly being used for various indications. Protocols for preparation and nomenclature of this biomaterial vary widely amongst authors and are often not well defined. Additionally, they are not uniformly documented in the literature, making results difficult to compare or replicate. In this paper we review the evolution and type of these products available for clinical use. Further we will discuss the scientific rational and technical aspects in preparation of these platelet biomaterials in order to administer them in various fields of medicine.

Senzel L, Gnatenko DV, Bahou WF (2009) The platelet proteome. Curr Opin Hematol 5:329–333CrossRef

Macaulay IC, Carr P, Gusnanto A et al (2005) Platelet genomics and proteomics in human health and disease. J Clin Invest 115:3370–3377CrossRefPubMedPubMedCentral

Mazzocca AD, McCarthy MB, Chowaniec DM et al (2012) The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. Am J Sports Med 40:1742–1749CrossRefPubMed

de Mos M, van der Windt AE, Jahr H et al (2008) Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 36:1171–1178CrossRefPubMed

Jo CH, Kim JE, Yoon KS, Shin S (2012) Platelet-rich plasma stimulates cell proliferation and enhances matrix gene expression and synthesis in tenocytes from human rotator cuff tendons with degenerative tears. Am J Sports Med 40:1035–1045CrossRefPubMed

Carofino B, Chowaniec DM, McCarthy MB et al (2012) Corticosteroids and local anesthetics decrease positive effects of platelet-rich plasma: an in vitro study on human tendon cells. Arthroscopy 28:711–719CrossRefPubMed

Visser LC, Arnoczky SP, Caballero O et al (2010) Growth factor-rich plasma increases tendon cell proliferation and matrix synthesis on a synthetic scaffold: an in vitro study. Tissue Eng Part A 16:1021–1029CrossRefPubMed

Cho HS, Song IH, Park SY et al (2011) Individual variation in growth factor concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean J Lab Med 31:212–218CrossRefPubMedPubMedCentral

Dohan Ehrenfest DM, Doglioli P, de Peppo GM et al (2010) Choukroun’s platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 55:185–194CrossRefPubMed

10.

Mishra A, Tummala P, King A et al (2009) Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods 15:431–435CrossRefPubMedPubMedCentral

11.

Xie X, Wang Y, Zhao C et al (2012) Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials 33:7008–7018CrossRefPubMed

12.

Drengk A, Zapf A, Stürmer EK, Stürmer KM, Frosch KH (2009) Influence of platelet-rich plasma on chondrogenic differentiation and proliferation of chondrocytes and mesenchymal stem cells. Cells Tissues Organs 189:317–326CrossRefPubMed

13.

Spreafico A, Chellini F, Frediani B et al (2009) Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem 108:1153–1165CrossRefPubMed

14.

van Buul GM, Koevoet WL, Kops N et al (2011) Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 39:2362–2370CrossRefPubMed

15.

Graziani F, Ivanovski S, Cei S et al (2005) The in vitro effect of different concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 17:212–219CrossRef

16.

García-Martínez O, Reyes-Botella C, Díaz-Rodríguez L et al (2012) Effect of platelet-rich plasma on growth and antigenic profile of human osteoblasts and its clinical impact. J Oral Maxillofac Surg 70:1558–1564CrossRefPubMed

17.

Anitua E, Sánchez M, del Mar Zalduendo M et al (2009) Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif 42:162–170CrossRefPubMed

18.

Kushida S, Kakudo N, Suzuki K, Kusumoto K (2013) Effects of platelet-rich plasma on proliferation and myofibroblastic differentiation in human dermal fibroblasts. Ann Plast 71(2):219–224CrossRef

19.

Browning SR, Weiser AM, Woolf N et al (2012) Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts. J Bone Joint Surg Am 94:1–7CrossRef

20.

Radosevich M, Goubran HA, Burnouf T (1997) Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 72:133–143CrossRefPubMed

21.

Mann KG (1999) Biochemistry and physiology of blood coagulation. Thromb Haemost 82:165–174PubMed

22.

Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11(2):123–134CrossRefPubMed

23.

Arai M, Ogita-Nakanishi H, Lee K et al (2012) Role of cytokines in lavage or drainage fluid after hemithyroidectomy in wound healing: involvement of histamine in the acceleration and delay of wound healing. Wound Repair Regen 20(2):158–165CrossRefPubMed

24.

Rosenthal AR, Egbert PR, Harbury C, Hopkins JL, Rubenstein E (1978) Use o platelet fibrinogen-thrombin mixture to seal experimental penetrating corneal wounds. Albrecht Von Graefes Arch Klin Exp Ophthalmol 207:111–115CrossRefPubMed

25.

Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL (1986) Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 204:322–330CrossRefPubMedPubMedCentral

26.

Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23:177–189CrossRefPubMedPubMedCentral

27.

Marx RE, Carlson ER, Eichstaedt RM, Georgeff KR et al (1998) Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85:638–646CrossRefPubMed

28.

Whitman DH, Berry RL, Green DM (1997) Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 55:1294–1299CrossRefPubMed

29.

Su CY, Kuo YP, Tseng YH, Su CH, Burnouf T (2009) In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108:56–61CrossRefPubMed

30.

Burnouf T, Lee CY, Luo CW et al (2012) Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. Biologicals 40:21–30CrossRefPubMed

31.

Marx RE (2001) Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 10(4):225–228CrossRefPubMed

32.

Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA (2009) Platelet rich plasma: from basic science to clinical applications. Am J Sports Med 37(11):2259–2272CrossRefPubMed

33.

Aster Richard H (2013) Blood platelet kinetics and platelet transfusion. J Clin Invest 123(11):4564–4565CrossRefPubMedPubMedCentral

34.

Reiss RF, Katz AJ (1976) Optimizing recovery of platelets in platelet-rich plasma by the simplex strategy. Transfusion 16:370–374CrossRefPubMed

35.

Mooren R, Hendriks EJ, van der Beuken J et al (2010) The effect of platelet-rich plasma in vitro on primary cells: rat osteoblast-like cells and human endothelial cells. Tissue Eng Part A 16:3159–3172CrossRefPubMed

36.

Ranly DM, McMillan J, Keller T et al (2005) Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation. A study of immunocompromised mice. J Bone Joint Surg Am 87:2052–2064PubMed

37.

Moojen DJ, Everts PA, Schure RM et al (2008) Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 26:404–410CrossRefPubMed

38.

Mazzocca AD, McCarthy MB, Chowaniec DM et al (2012) Platelet rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am 94:308–316CrossRefPubMed

39.

Moojen DJ, Everts PA, Schure RM et al (2008) Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 26:404–410CrossRefPubMed

40.

Castillo TN, Pouliot MA, Kim HJ et al (2011) Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 39:266–271CrossRefPubMed

41.

Werther K, Christensen IJ, Nielsen HJ (2002) Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 62:343–350CrossRefPubMed

42.

Lopez-Vidriero E, Goulding KA, Simon DA et al (2010) The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy 26:269–278CrossRefPubMed

43.

Mei-Dan O, Mann G, Maffulli N (2010) Platelet-rich plasma: any substance to it? Br J Sports Med 44:618–619CrossRefPubMed

44.

DeLong JM, Russell RP, Mazzocca AD (2012) Platelet-rich plasma: the PAW classification system. Arthroscopy 28:998–1009CrossRefPubMed

45.

Sonker A, Dubey A (2015) Determining the effect of preparation and storage: an effort to streamline platelet components as a source of growth factors for clinical application. Transfus Med Hemother 42:174–180CrossRefPubMedPubMedCentral

46.

Mann KG (1999) Biochemistry and physiology of blood coagulation. Thromb Haemost 82:165–174PubMed

47.

Han B, Woodell-May J, Ponticiello M et al (2009) The effect of thrombin activation of platelet rich plasma on demineralized bone matrix osteoinductivity. J Bone Joint Surg Am 91:1459–1770CrossRefPubMed

48.

Ledent E, Wasteson A, Berlin G (1995) Growth factor release during preparation and storage of platelet concentrates. Vox Sang 68:205–209CrossRefPubMed

49.

Wadhwa M, Seghatchian MJ, Lubenko A, Contreras M, Dilger P, Bird C, Thorpe R (1996) Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haematol 93:225–234CrossRefPubMed

50.

Fujihara M, Ikebuchi K, Wakamoto S, Sekiguchi S (1999) Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor-β1 in apheresis platelet concentrates during storage. Transfusion 39:498–505CrossRefPubMed

51.

Murphy S (1985) Platelet storage for transfusion. Semin Hematol 22:165–177PubMed

52.

Liu Y, Kalén A, Risto O, Wahlström O (2002) Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen 10(5):336–340CrossRefPubMed

53.

McCarrel TM, Minas T, Fortier LA (2012) Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 94(19):e143(1-8)CrossRef

54.

Weibrich G, Kleis WK, Hitzler WE, Hafner G (2005) Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants 20(1):118–123PubMed

55.

Arshdeep, Kumaran MS (2014) Platelet-rich plasma in dermatology: Boon or a bane? Indian J Dermatol Venereol Leprol 80:5–14

56.

Arora NS, Ramanayake T, Ren YF, Romanos GE (2009) Platelet-rich plasma: a literature review. Implant Dent 18(4):303–310CrossRefPubMed

Title: Platelet Derived Biomaterials for Therapeutic Use: Review of Technical Aspects
Authors: Satyam Arora
Naveen Agnihotri
Publication date: 01-06-2017
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 2/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-016-0669-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016

Patterns of Adverse Transfusion Reactions in a Tertiary Care Centre of North India: A Step Towards Hemovigilance

Erratum to: Platelet Derived Biomaterials for Therapeutic Use: Review of Technical Aspects

Clinically Significant IgM Anti-Cw: A Rare Report

Neonatal Outcomes of Pregnancy with Immune Thrombocytopenia

Bacteremia During Early Post-allogeneic Hematopoietic Stem Cell Transplantation Period: A Single Center Experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer